This is the first randomized phase II, open-label, multicenter study to compare the efficacy and safety of SOX+bevacizumab with SOX+cetuximab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS. Here, KRAS is linked to colorectal cancer.